Treatment Response and the quality of life of ch. Hepatitis C patients
8 Angebote vergleichen
Bester Preis: € 37,30 (vom 04.12.2019)1
Treatment Response and the quality of life of ch. Hepatitis C patients (2017)
~EN PB NWISBN: 9783330350076 bzw. 3330350075, vermutlich in Englisch, LAP LAMBERT Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Lieferbar in 2 - 3 Tage.
Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication; the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: · Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. · Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. · Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. Taschenbuch, 08.08.2017.
Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication; the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: · Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. · Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. · Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. Taschenbuch, 08.08.2017.
2
Treatment Response and the quality of life of ch. Hepatitis C patients
~EN PB NWISBN: 9783330350076 bzw. 3330350075, vermutlich in Englisch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
Treatment Response and the quality of life of ch. Hepatitis C patients: Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: · Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. · Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. · Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. Englisch, Taschenbuch.
Treatment Response and the quality of life of ch. Hepatitis C patients: Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: · Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. · Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. · Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. Englisch, Taschenbuch.
3
Treatment Response and the quality of life of ch. Hepatitis C patients (2017)
DE PB NWISBN: 9783330350076 bzw. 3330350075, in Deutsch, 88 Seiten, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland.
Von Händler/Antiquariat, Rheinberg-Buch, [3813847].
Neuware - Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. 08.08.2017, Taschenbuch, Neuware, 220x150x5 mm, 147g, 88, Internationaler Versand, PayPal, offene Rechnung, Banküberweisung, sofortueberweisung.de.
Von Händler/Antiquariat, Rheinberg-Buch, [3813847].
Neuware - Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. 08.08.2017, Taschenbuch, Neuware, 220x150x5 mm, 147g, 88, Internationaler Versand, PayPal, offene Rechnung, Banküberweisung, sofortueberweisung.de.
4
Treatment Response and the quality of life of ch. Hepatitis C patients
~EN NW ABISBN: 9783330350076 bzw. 3330350075, vermutlich in Englisch, neu, Hörbuch.
Lieferung aus: Niederlande, Lieferzeit: 5 Tage, zzgl. Versandkosten.
Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication, the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: · Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. · Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. · Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models.
Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication, the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: · Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. · Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. · Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models.
5
Treatment Response and the quality of life of ch. Hepatitis C patients (2017)
DE PB NWISBN: 9783330350076 bzw. 3330350075, in Deutsch, 88 Seiten, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, AHA-BUCH GmbH, [4009276].
Neuware - Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. -, 08.08.2017, Taschenbuch, Neuware, 220x150x5 mm, 147g, 88, Internationaler Versand, PayPal, Kreditkarte, offene Rechnung, Banküberweisung, offene Rechnung (Vorkasse vorbehalten).
Von Händler/Antiquariat, AHA-BUCH GmbH, [4009276].
Neuware - Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. -, 08.08.2017, Taschenbuch, Neuware, 220x150x5 mm, 147g, 88, Internationaler Versand, PayPal, Kreditkarte, offene Rechnung, Banküberweisung, offene Rechnung (Vorkasse vorbehalten).
6
Treatment Response and the quality of life of ch. Hepatitis C patients (2017)
DE PB NWISBN: 9783330350076 bzw. 3330350075, in Deutsch, 88 Seiten, LAP Lambert Academic Publishing, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland.
Von Händler/Antiquariat, Buchhandlung Hoffmann, [3174608].
Neuware - Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. 08.08.2017, Taschenbuch, Neuware, 220x150x5 mm, 147g, 88, Internationaler Versand, offene Rechnung (Vorkasse vorbehalten), sofortueberweisung.de, Selbstabholung und Barzahlung, Skrill/Moneybookers, PayPal, Lastschrift, Banküberweisung.
Von Händler/Antiquariat, Buchhandlung Hoffmann, [3174608].
Neuware - Hepatitis C virus (HCV) is a leading cause of liver cirrhosis and cancerin the world. Egypt has the highest HCV prevalence which is the leading cause of chronic hepatitis C in the country. This chronic infection can be treated with medication the standard therapy is a combination of Pegylated interferon alpha plus ribavirin(PEG-INF/RBV). The aim of the present work was to study the treatment response of PEG-INF/RBVcombination therapy and the health related quality of life (HRQOL) of CHC patients at GamalAbd El-Naser Hospital, Alexandria. The main recommendations of the study are: Regular evaluation of the HRQOL of CHC patients, especially those at risk of poor treatment response, is recommended. In addition, the prevalence of HCV, as an indicator of treatment response, must be monitored. Continuation of successful clinical trials onSovaldi and comparing the factors affecting its response among CHC patients as compared to PEG-IFN/RBV results. Understanding the transmission dynamics of HCV in Egypt, new infections and possibility of eradication of the disease using epidemiological models. 08.08.2017, Taschenbuch, Neuware, 220x150x5 mm, 147g, 88, Internationaler Versand, offene Rechnung (Vorkasse vorbehalten), sofortueberweisung.de, Selbstabholung und Barzahlung, Skrill/Moneybookers, PayPal, Lastschrift, Banküberweisung.
8
Treatment Response and the quality of life of ch. Hepatitis C patients
~EN PB NWISBN: 3330350075 bzw. 9783330350076, vermutlich in Englisch, LAP Lambert Academic Publishing, Taschenbuch, neu.
Treatment Response and the quality of life of ch. Hepatitis C patients ab 49.9 € als Taschenbuch: . Aus dem Bereich: Bücher, English, International, Gebundene Ausgaben,.
Lade…